COVID-19住院合并肌钙蛋白升高患者心肌受累的前瞻性多中心观察研究
该研究纳入英国25家医院342例COVID-19合并肌钙蛋白升高患者,出院28天内行心脏磁共振,并与64例肌钙蛋白正常COVID-19患者和113例无COVID-19但合并症匹配者对照。结果显示病例组心脏异常、心室功能受损和心肌瘢痕更常见,但心肌炎比例低,瘢痕机制多样包括微梗死。心肌瘢痕是12个月主要不良心血管事件的独立预测因素。
要点
- COVID-19合并肌钙蛋白升高者出院早期心脏异常达61%,显著高于对照组。
- probable近期心肌炎比例仅6.7%,但心肌梗死和微梗死模式更常见。
- 心肌瘢痕而非COVID-19感染或肌钙蛋白水平独立预测12个月MACE。
核心结论
- COVID-19合并肌钙蛋白升高患者出院早期心室功能受损和心肌瘢痕更常见,但心肌炎比例低,瘢痕机制多样包括微梗死。
- 心肌瘢痕是12个月主要不良心血管事件的独立预测因素。
研究设计与样本
- 前瞻性、多中心、观察性研究,在英国25家医院于2020年6月至2021年3月招募342例COVID-19合并肌钙蛋白升高患者,出院28天内行心脏磁共振。
- 另设两个前瞻性对照组:64例COVID-19且肌钙蛋白正常患者和113例无COVID-19但年龄与心血管合并症匹配者。
- 采用回归模型分析12个月主要不良心血管事件的预测因素。
主要发现
- 共纳入519例患者,356例(69%)为男性,中位年龄61.0岁(四分位距53.8-68.8)。
- 任何心脏异常(左或右心室功能受损、瘢痕或心包疾病)在病例组为61%(207/342),高于对照组36%(COVID+/troponin-)和31%(COVID-/comorbidity+),P均<0.001。
- 心室功能受损在病例组为17.2%,对照组分别为3.1%和7.1%;瘢痕在病例组为42%,对照组分别为7%和23%,P均<0.001。
- 心肌损伤模式不同:梗死病例组13% vs 对照组2%和7%(P<0.01);微梗死9% vs 0%和1%(P<0.001);非缺血性瘢痕无差异(13% vs 5%和14%,P=0.10)。
- 采用Lake Louise磁共振标准, probable近期心肌炎在病例组为6.7%(23/342),无COVID-19对照组为1.7%(2/113),P=0.045。
关键数值与推荐
- 心脏异常定义:左或右心室功能受损、瘢痕或心包疾病。
- probable近期心肌炎依据Lake Louise磁共振成像标准判定。
- 主要不良心血管事件随访12个月,心肌瘢痕OR 2.25(95%CI 1.12-4.57),P=0.02。
临床怎么用
- 对COVID-19住院期间肌钙蛋白升高患者,出院早期应考虑心脏磁共振评估心肌受累。
- 心肌瘢痕提示12个月MACE风险增高,需加强随访管理。
- 心肌炎比例低,瘢痕机制多样,治疗应针对具体损伤模式而非一概按心肌炎处理。
局限性
- 观察性研究,不能确立因果关系。
- 对照组样本量较小,可能存在选择偏倚。
- 随访期间MACE事件数较少,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute myocardial injury in hospitalized patients with coronavirus disease 2019 (COVID-19) has a poor prognosis. Its associations and pathogenesis are unclear. Our aim was to assess the presence, nature, and extent of myocardial damage in hospitalized patients with troponin elevation. METHODS: Across 25 hospitals in the United Kingdom, 342 patients with COVID-19 and an elevated troponin level (COVID+/troponin+) were enrolled between June 2020 and March 2021 and had a magnetic resonance imaging scan within 28 days of discharge. Two prospective control groups were recruited, comprising 64 patients with COVID-19 and normal troponin levels (COVID+/troponin-) and 113 patients without COVID-19 or elevated troponin level matched by age and cardiovascular comorbidities (COVID-/comorbidity+). Regression modeling was performed to identify predictors of major adverse cardiovascular events at 12 months. RESULTS: Of the 519 included patients, 356 (69%) were men, with a median (interquartile range) age of 61.0 years (53.8, 68.8). The frequency of any heart abnormality, defined as left or right ventricular impairment, scar, or pericardial disease, was 2-fold greater in cases (61% [207/342]) compared with controls (36% [COVID+/troponin-] versus 31% [COVID-/comorbidity+]; P<0.001 for both). More cases than controls had ventricular impairment (17.2% versus 3.1% and 7.1%) or scar (42% versus 7% and 23%; P<0.001 for both). The myocardial injury pattern was different, with cases more likely than controls to have infarction (13% versus 2% and 7%; P<0.01) or microinfarction (9% versus 0% and 1%; P<0.001), but there was no difference in nonischemic scar (13% versus 5% and 14%; P=0.10). Using the Lake Louise magnetic resonance imaging criteria, the prevalence of probable recent myocarditis was 6.7% (23/342) in cases compared with 1.7% (2/113) in controls without COVID-19 (P=0.045). During follow-up, 4 patients died and 34 experienced a subsequent major adverse cardiovascular event (10.2%), which was similar to controls (6.1%; P=0.70). Myocardial scar, but not previous COVID-19 infection or troponin, was an independent predictor of major adverse cardiovascular events (odds ratio, 2.25 [95% CI, 1.12-4.57]; P=0.02). CONCLUSIONS: Compared with contemporary controls, patients with COVID-19 and elevated cardiac troponin level have more ventricular impairment and myocardial scar in early convalescence. However, the proportion with myocarditis was low and scar pathogenesis was diverse, including a newly described pattern of microinfarction. REGISTRATION: URL: https://www.isrctn.com; Unique identifier: 58667920.
引用
- Artico J, Shiwani H, Moon JC, et al. Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study. Circulation. 2023. PMID: 36705028. doi:10.1161/CIRCULATIONAHA.122.060632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。